{"id":"NCT04053387","sponsor":"Organon and Co","briefTitle":"Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)","officialTitle":"A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-13","primaryCompletion":"2021-04-06","completion":"2021-04-06","firstPosted":"2019-08-12","resultsPosted":"2022-08-08","lastUpdate":"2025-08-06"},"enrollment":763,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"tapinarof cream, 1%","otherNames":["DMVT-505"]}],"arms":[{"label":"Tapinarof (DMVT-505) Cream Group","type":"EXPERIMENTAL"}],"summary":"This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.","primaryOutcome":{"measure":"Number of Subjects With Adverse Events and Serious Adverse Events","timeFrame":"Baseline to 44 weeks","effectByArm":[{"arm":"Continuous or Intermittent Use of Tapinarof (DMVT-505) Cream According to PGA Score","deltaMin":474,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":104,"countries":["United States","Canada"]},"refs":{"pmids":["40600584","37697121"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":763},"commonTop":["Folliculitis","Dermatitis contact"]}}